A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and an Open-Label Study to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants

Trial Profile

A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and an Open-Label Study to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs JNJ-61803534 (Primary) ; Midazolam
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 09 Nov 2017 Planned number of patients changed from 108 to 124.
    • 09 Nov 2017 Planned End Date changed from 20 Jun 2018 to 20 Nov 2018.
    • 09 Nov 2017 Planned primary completion date changed from 7 Dec 2017 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top